Physician profile
Daniel J Canter
NPI 1689730061
$328,565.60
in general payments reported to CMS, 2019-2025
47 companies · $5,962 in 2025
The $5,962 reported for 2025 was more than what 91% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $4,488 · 2021: $30K · 2022: $157K · 2023: $64K · 2024: $50K · 2025: $5,962.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Consulting Fee: $22K · Travel and Lodging: $17K · Food and Beverage: $3,656 · Education: $8.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,712.50 |
| Consulting Fee | $22,483.00 |
| Travel and Lodging | $17,373.79 |
| Food and Beverage | $3,655.92 |
| Education | $8.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $116,886.67 | 2020-2025 | Erleada, Akeega, Rybrevant |
| Myovant Sciences INC. | $65,888.67 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57,436.83 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $25,325.71 | 2019-2025 | Truqap, Lynparza |
| Ferring Pharmaceuticals INC. | $23,917.07 | 2024-2025 | Adstiladrin |
| Progenics Pharmaceuticals, INC. | $16,801.71 | 2022-2025 | Pylarify |
| Eli Lilly and Company | $3,875.97 | 2023 | |
| Myriad Genetic Laboratories, INC. | $3,868.26 | 2020-2025 | Prolaris |
| Janssen Global Services, LLC | $3,510.00 | 2025 | |
| Dendreon Pharmaceuticals LLC | $2,041.93 | 2020-2025 | Provenge |
| Bayer Healthcare Pharmaceuticals INC. | $1,973.54 | 2020-2025 | |
| Janssen Scientific Affairs, LLC | $1,632.71 | 2021-2025 | Erleada, Akeega |
| Accord Healthcare, INC. | $1,434.82 | 2021-2025 | |
| Pfizer INC. | $1,396.73 | 2020-2025 | |
| Astellas Pharma US INC | $745.33 | 2019-2022 |
Show all 44 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Canter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.